Clinical study of tissue plasminogen activator in the treatment of subretinal hemorrhage

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041588

Enrollment

Unknown

Registered

2020-12-31

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subretinal hemorrhage

Interventions

Treatment:tPA+anti-VEGF

Eligibility

Sex/Gender

All

Age

14 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with subretinal hemorrhage involving the macular region.

Exclusion criteria

Exclusion criteria: 1. Patients with severe systemic diseases; 2. Patients taking anticoagulants; 3. Patients who cannot be followed up.

Design outcomes

Primary

Measure	Time frame
Hemorrhage;visual acuity;visualacuity;hemorrghage;	—

Secondary

Measure	Time frame
duration;	—

Countries

China

Contacts

Public ContactXuejiao Qin

Qilu Hospital of Shandong University

qinxuejiao@hotmail.com+86 18560087100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026